We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Enveric Biosciences has announced the acquisition of an exclusive and perpetual licence for Diverse Biotech’s novel molecules to treat oncology and other debilitating diseases.